Last reviewed · How we verify
SGX942
SGX942 is a recombinant human platelet-derived growth factor isoform BB (PDGF-BB) used to promote wound healing.
SGX942 is a recombinant human platelet-derived growth factor isoform BB (PDGF-BB) used to promote wound healing. Used for Treatment of cutaneous squamous cell carcinoma (cSCC) and other cutaneous malignancies.
At a glance
| Generic name | SGX942 |
|---|---|
| Also known as | Dusquetide |
| Sponsor | Soligenix |
| Drug class | Growth factor |
| Target | PDGF-BB |
| Modality | Small molecule |
| Therapeutic area | Wound healing |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating the proliferation and migration of fibroblasts and other cells involved in wound repair, promoting tissue regeneration and accelerating the healing process.
Approved indications
- Treatment of cutaneous squamous cell carcinoma (cSCC) and other cutaneous malignancies
Common side effects
- Injection site reactions
- Fatigue
- Nausea
Key clinical trials
- Dusquetide for the Treatment of Behcet's Disease (PHASE2)
- DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer (PHASE3)
- A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |